Special Report: Personalised audio technology provider Audeara will expand it footprint in the Australian market after entering a strategic reseller agreement with George & Matilda Eyecare for Audeara products to be offered through the group’s network of stores.
Audeara Limited (ASX:AUA) revealed that, as part of the agreement, George & Matilda Eyecare will initially stock Audeara’s branded assistive listening devices, commencing with the company’s Audeara Buds – a state-of-the-art in-ear solution, driven by advanced AI-powered hearing technology – to customers to highlight how personalised audio solutions complement effectiveness of tailored optical care and reinforce the importance of individualised sensory health.
The company said George & Matilda Eyecare would initially stock Buds product, with an aim to broaden to Audeara’s full suite of audiology solutions for patients who may not yet require hearing aids.
This move opens an important new sales channel for Audeara, providing consumers with access to personalized audio solutions that enhance everyday sensory experiences.
Established in 2016 George & Matilda Eyecare is a leading independent optical network with more than 115 practices, servicing 140 communities across Australia.
Audeara said it expected first sales from George & Matilda Eyecare stores in the coming weeks.
The agreement with George & Matilda Eyecare broadens Audeara’s existing 1,500-clinic footprint in Australia and aligns with its stated strategy in the local market of expanding with healthcare partners and retail groups.
Looking ahead, Audeara envisions a natural progression in the sector, where a full range of sensory solutions, like merging prescription (personalised) audio with prescription glasses, could further enrich the consumer journey. This approach represents a seamless integration of vision and hearing care, positioning Audeara to meet the evolving demands of modern health and lifestyle needs.
Audeara said its well-established presence in the Australian market also provides a strong platform for the continued momentum of its AUA Technology division in international markets.
Its growth internationally has recently been highlighted by a follow-up purchase order valued at US$917,000 (A$1.48m) from a global music instrument manufacturer and launch of co-branded products with Clinico Inc., Taiwan’s largest hearing aid retailer.
George & Matilda Eyecare CEO Chris Beer said the company was excited to collaborate with Audeara and add its assisted listening device solutions to an existing range of hearing aids.
“Our goal has always been to provide the best optical and audiology care to our patients, and now we are extending this care to additional patients with a high-calibre partner in Audeara,” he said.
Audeara’s CEO and managing director Dr James Fielding said the company was excited to have executed an agreement with George & Matilda Eyecare, a trusted name in the Australian eye health and optical retail segment.
“Their reputation, Australian market footprint, and our innovative audio technology have the potential to reach a broad customer base who are expected to considerably benefit from the company’s solutions,” he said.
“Importantly, this agreement will unlock another sales channel in the Australian market for the company’s hardware products and build on our established footprint of 1,500 clinics.
“We look forward to working alongside the group’s personnel to educate them on our solutions in the coming weeks.”
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.